RICERCA ITALIANA     

Programmi di ricerca simili:

• 1 - Patogenesi molecolare ed analisi sequenziale di interazioni cellulari e marcatori biologici di progressione di malattia e di resistenza al trattamento nella leucemia linfatica cronica
• 2 - Nuove frontiere nella stratificazione delle leucemie acute linfoidi (LAL): integrazione tra citogenetica non-convenzionale, genomica e post-genomica
• 3 - PROGRESSIONE DA MGUS A MIELOMA MULTIPLO: PATOGENESI MOLECOLARE, IDENTIFICAZIONE DI POTENZIALI MARCATORI PROGNOSTICI E SVILUPPO PRECLINICO DI RAZIONALI APPROCCI CHEMIOPREVENTIVI
• 4 - Un approccio biomolecolare per la patologia HHV8-associata e la sua possibile trasformazione neoplastica:
• 5 - Eritropoiesi normale e patologica: caratterizzazione molecolare mediante tecnologie avanzate a resa elevata.
• 6 - Il fattore di trascrizione NF-kB nella regolazione del differenziamento ed apoptosi del sistema immune.
• 7 - Implicazioni diagnostico-terapeutiche delle nuove conoscenze cliniche e molecolari del carcinoma midollare della tiroide.
• 8 - Meccanismi della citochinesi: identificazione di nuovi geni coinvolti nel processo e nella sua regolazione
• 9 - Immunità umorale nella sclerosi multipla: attivazione dei linfociti B e demielinizzazione
• 10 - Patogenesi molecolare delle malattie del motoneurone come tool per l’identificazione di nuovi approcci terapeutici biomolecolari e cellulari

Classificazione scientifico-disciplinare

• Area scientifico disciplinare: Scienze mediche
  • ANATOMIA PATOLOGICA
  • MALATTIE DEL SANGUE

Classificazione brevettuale

• CHEMISTRY; METALLURGY
  • BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF (biocides, pest repellants or attractants, or plant growth regulators, containing micro-organisms, viruses, microbial fungi, enzymes, fermentates or substances produced by or extracted from micro-organisms or animal material A01N63/00; food compositions A21, A23; medicinal preparations A61K; chemical aspects of, or use of materials for, bandages, dressings, absorbent pads or surgical articles A61L; fertilisers C05); PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS (preservation of living parts of humans or animals A01N1/02); MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (micro-biological testing media C12Q)

Classificazione geografica

• Regione: Toscana

Bibliografia

BIBLIOGRAFIA
1. World Health Organization classification of tumours. Pathology & genetics: Tumours of haematopoietic and lymphoid tissues. Lyon: IARC Press, International Agency for Research on Cancer, 2001.
2. Arcaini L, et al. Splenic and nodal marginal zone lymphomas are indolent disorders at high hepatitis C virus seroprevalence with distinct presenting features but similar morphologic and phenotypic profiles. Cancer. 2004 Jan 1;100(1):107-15.
3 Hermine O, et al. Regression of splenic lymphoma with villous lymphocytes after treatment of hepatitis C virus infection. N Engl J Med 2002;347:89-94
4. Roses AD. Pharmacogenetics and drug development: the path to safer and more effective drugs. Nat Rev Genet. 2004 Sep;5(9):645-56.
5. Need AC, et al. Priorities and standards in pharmacogenetic research. Nat Genet. 2005 Jul;37(7):671-81.
6. Bellan C, et al. Burkitt's lymphoma: new insights into molecular pathogenesis. J Clin Pathol. 2003 Mar;56(3):188-92.
7. Bellan C, et al. Immunoglobulin gene analysis reveals 2 distinct cells of origin for EBV-positive
and EBV-negative Burkitt lymphomas. Blood, 2005 Aug 1;106(3):1031-6. Epub 2005 Apr 19.
8. Rizvi MA, et al. T-cell non-Hodgkin lymphoma. Blood. 2006 Feb 15;107(4):1255-64. Epub 2005 Oct 6.
9. Lyon, IARC Press, International Agency for Researche on Cancer, 2001.
10. Martinez-Delgado B, et al.Expression profiling of T-cell lymphomas differentiates peripheral and lymphoblastic lymphomas and defines survival related genes. Clin Cancer Res. 2004 Aug 1;10(15):4971-82.
11. Ballester B, et al. Gene expression profiling identifies molecular subgroups among nodal peripheral T-cell lymphomas. Oncogene. 2006 Mar 9;25(10):1560-70.
12. Piccaluga PP, et al. Expression of platelet-derived growth factor receptor alpha in peripheral T-cell lymphoma not otherwise specified. Lancet Oncol. 2005 Jun;6(6):440.
13. Ambrogio C, et al. p130Cas mediates the transforming properties of the anaplastic lymphoma kinase. Blood. 2005 Dec 1;106(12):3907-16.
14. Waldmann TA, et al. Rearrangements of genes for the antigen receptor on T cells as markers of lineage and clonality in human lymphoid neoplasms. N Engl J Med. 1985;313:776–783.
15. Waldmann TA. The arrangement of immunoglobulin and T cell receptor genes in human lymphoproliferative disorders. Adv Immunol.1987;40:247–321.
16. Arnold A, et al. Immunoglobulin-gene rearrangements as unique clonal markers in human lymphoid neoplasms. N Engl J Med. 1983;309:1593–1599.
17. Battey J, et al. The human c-myc oncogene: structural consequences of translocation into the IgH locus in Burkitt lymphoma. Cell. 1983;34:779–787.
18. Tsujimoto Y, et al. Molecular cloning of the chromosomal breakpoint of B-cell lymphomas and leukemias with the t(11;14) chromosome translocation. Science. 1984;224:1403– 1406.
19. Bakhshi A, et al. Cloning the chromosomal breakpoint of t(14;18) human lymphomas: clustering around JH on chromosome 14 and near a transcriptional unit on 18. Cell. 1985;41:899–906.
20. Lovec H, et al. Cyclin D1/bcl-1 cooperates with myc genes in the generation of B-cell lymphoma in transgenic mice. EMBO J. 1994;13:3487–3495.
21. Hockenbery DM. The bcl-2 oncogene and apoptosis. Semin Immunol. 1992;4:413–420.
22. Saiki RK, et al. Enzymatic amplification of beta-globin genomic sequences and restriction site analysis for diagnosis of sickle cell anemia. Science. 1985;230:1350–1354.
23. Hooberman AL. The use of the polymerase chain reaction in clinical oncology. Oncology (Huntingt).1992;6:25–34.
24. Chan WC, Greiner TC. Diagnosis of lymphomas by the polymerase chain reaction. Am J Clin Pathol. 1994;102:273–274.
25. Elmberger PG, et al. Transcripts of the npm-alk fusion gene in anaplastic large cell lymphoma, Hodgkin disease, and reactive lymphoid lesions. Blood. 1995;86:3517–3521.
26. Orlando C, et al. Developments in quantitative PCR. Clin Chem Lab Med. 1998;36:255–269.
27. Gerard CJ, et al. Improved quantitation of minimal residual disease in multiple myeloma using real-time polymerase chain reaction and plasmid-DNA complementarity determining region III standards. Cancer Res. 1998;58:3957–3964.
28. Luthra R, et al. Novel 59 exonuclease-based real-time PCR assay for the detection of t(14;18)(q32;q21) in patients with follicular lymphoma. Am J Pathol. 1998;153:63–68.
29. Willis TG, Dyer MJ. The role of immunoglobulin translocations in the pathogenesis of B-cell malignancies. Blood. 2000;96:808–822.
30. Auer IA, Gascoyne RD, Connors JM, et al. t(11;18)(q21;q21) is the most common translocation in MALT lymphomas. Ann Oncol. 1997;8:979–985.
31. Streubel B, et al. T(14;18)(q32;q21) involving IGH and MALT1 is a frequent chromosomal aberration in MALT lymphoma. Blood. 2003;101:2335–2339.
32. Liu H, et al. Resistance of t(11;18). positive gastric mucosa-associated lymphoid tissue lymphoma to Helicobacter pylori eradication therapy. Lancet. 2001;357:39–40.
33. Starostik P, et al. Gastric marginal zone B-cell lymphomas of MALT type develop along 2 distinct pathogenetic pathways. Blood.
2002;99:3–9.
34. Gascoyne RD, et al. Prognostic significance of anaplastic lymphoma kinase (ALK) protein expression in adults with anaplastic large cell lymphoma. Blood. 1999 Jun 1;93(11):3913-21.
35. Falini B, et al. Lymphomas expressing ALK fusion protein(s) other than NPM-ALK. Blood. 1999 Nov 15;94(10):3509-15.
36. Cinti C, et al. Genetic alterations of the retinoblastoma-related gene RB2/p130 identify different pathogenetic mechanisms in and among Burkitt's lymphoma subtypes. Am J Pathol. 2000 Mar;156(3):751-60.
37. Greiner TC, et al. p53 mutations in mantle cell lymphoma are associated with variant cytology and predict a poor prognosis. Blood. 1996;87:4302–4310.
38. Pinyol M, Hernandez L, Cazorla M, et al. Deletions and loss of expression of p16INK4a and p21Waf1 genes are associated with aggressive variants of mantle cell lymphomas. Blood. 1997;89:272–280.
39. Gronbaek K, et al. Concurrent disruption of p16INK4a and the ARF-p53 pathway predicts poor prognosis in aggressive nonHodgkin’s lymphoma. Leukemia. 2000;14:1727–1735.
40. Sanchez-Beato M, et al. Overall survival in aggressive B-cell lymphomas is dependent on the accumulation of alterations in p53, p16, and p27. Am J Pathol. 2001;159:205–213.
41. Sander CA, et al. p53 mutation is associated with progression in follicular lymphomas. Blood. 1993;82:1994–2004.
42. Ichikawa A, et al. Mutations of p53 gene and their relation to disease progression in B-cell lymphoma. Blood.1992;79:2701–2707.
43. Lo Coco F, et al. p53 mutations are associated with histologic transformation of follicular lymphoma. Blood. 1993;82:2289–2295.
44. Baker SJ, et al. Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas. Science. 1989;244:217–221.
45. Ohtani-Fujita N, et al. CpG methylation inactivates the promoter activity of the human retinoblastoma tumorsuppressor gene. Oncogene. 1993;8:1063–1067.
46. Gonzalez-Zulueta M, et al. Methylation of the 59 CpG island of the p16/CDKN2 tumor suppressor gene in normal and transformed human tissues correlates with gene silencing. Cancer Res. 1995;55:4531–4535.
47. Staudt LM, Brown PO. Genomic views of the immune system. Annu Rev Immunol.2000;18:829–859.
48. Alizadeh A, et al. The lymphochip: a specialized cDNA microarray for the genomic-scale analysis of gene expression in normal and malignant lymphocytes. Cold Spring Harb Symp Quant Biol. 1999;64:71–78.
49. Eisen MB, Brown PO. DNA arrays for analysis of gene expression. Methods Enzymol. 1999;303:179–205.
50. Alizadeh AA, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000;403:503–511.
51. Rosenwald A, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med. 2002;346:1937–1947.
52. Wright G, et al. A gene expression–based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma. Proc Natl Acad Sci U S A. 2003;100:9991–9996.

Parole Chiave

LINFOMI NON HODGKIN, ANALISI MOLECOLARE, ANALISI DELL'ESPRESSIONE GENICA, SILENZIAMENTO DELLRNA, PROGNOSI, RISPOSTA ALLA TERAPIA, ARRAY-COMPARATIVE GENOMIC HIBRIDIZATION (CGH), SINGLE NUCLEOTIDE POLYMORPHISMS (SNPS), CELL SIGNALING